South Africa is preparing for a vaccine that does not yet exist as an approved medicine.
That distinction matters. M72/AS01E is still being tested in a Phase 3 trial. Its results are not yet known, and any successful candidate would still require regulatory approval. But if it succeeds, it could become the first new TB vaccine introduced in more than a century and the first intended to protect adolescents and adults.
The trial enrolled about 20,000 participants across 54 sites in South Africa, Kenya, Malawi, Zambia and Indonesia. Cabinet says government is preparing for possible registration and introduction, while a manufacturing agreement has been reached with the Serum Institute of India.
Planning early is wise. It also forces the moral question early.
Will the people who helped carry the research also be among the first able to carry its benefit?
Access is not secured by scientific success alone. It depends on price, manufacturing, registration, cold chains, staffing, public trust and whether a rural clinic can deliver what a laboratory has proved.
ScriptureWhen a man excluded by leprosy asks whether Jesus is willing to make him clean, Jesus draws near, touches him and answers with willing mercy.
Mark 1:40–42
A vaccine is not salvation, and medicine should never be asked to bear the weight of the gospel. But preventing disease is a gift of common grace. Christians should be among those insisting that such gifts are not reserved for whoever can pay first or live nearest to the strongest system.
That does not require pretending supply is limitless. It requires naming the whole delivery problem now: transparent evidence, fair pricing, local capacity, rural access and honest communication about what the trial does and does not show.
The possibility of tomorrow’s vaccine must not distract from today’s duties either: testing, treatment completion, preventive therapy and care for people already living with TB remain urgent.
South Africa should not celebrate a hypothetical result before the evidence arrives. Neither should it wait for success before asking who might be left behind.
A breakthrough is not complete when a vaccine works. It is complete when the person most exposed to disease can receive it.
